Table 1.
Patient characteristics
| Parameter | N = 131 |
|---|---|
| Median age, y (range) | 62 (40‐85) |
| Gender | |
| Male, n (%) | 79 (60.31) |
| Female, n (%) | 52 (39.69) |
| Immunoglobulin type, n (%) | |
| IgG | 62 (47.33) |
| IgA | 24 (18.32) |
| IgM | 1 (0.8) |
| IgD | 9 (6.9) |
| Light chain only | |
| Kappa | 12 (9.16) |
| Lambda | 18 (13.74) |
| Non‐secretory, n (%) | 5 (3.82) |
| Median beta‐2‐microglobulin, mg/L (range) | 12.5 (1.2‐76.2) |
| Median lactate dehydrogenase U/L (range) | 164 (53‐913) |
| Median albumin, g/dL (range) | 3.3 (1.3‐4.9) |
| Median calcium, mmol/L (range) | 2.19 (1.67‐4.04) |
| Median creatinine, µmol/lL (range) | 101.7 (35‐1692.9) |
| Median hemoglobin, g/dL (range) | 7.9 (3.0‐15.2) |
| ISS, n (%) | |
| I | 9 (6.87) |
| II | 72 (54.96) |
| III | 50 (38.17) |
| Treatment, n (%) | |
| Bortezomib based | 47 (35.88) |
| Thalidomide based | 84 (64.12) |